Vitrafy Life Sciences Limited (ASX: VFY)

Market Cap	105.35M
Revenue (ttm)	37.17K
Net Income (ttm)	-10.43M
Shares Out	63.85M
EPS (ttm)	-3.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,263
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	1.705 - 2.040
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Vitrafy Life Sciences

Vitrafy Life Sciences Limited provides cryopreservation solutions in Australia. Its cryopreservation technology improves the cell survival of cryopreserved biological materials, such as blood platelets used to treat trauma patients, t cells used in cancer treatments, and animal sperm used in breeding and farming. The company provides smart freezing device, smart thawing device, and LifeChain, a sample quality management software platform, as well as smart blood bag and sperm packaging solution. It serves animal genetics and animal reproduction ...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2017
• Employees: 22
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: VFY

Financial Performance

In 2024, Vitrafy Life Sciences's revenue was 37,166, a decrease of -98.19% compared to the previous year's 2.06 million. Losses were -10.43 million, 33.4% more than in 2023.